1Zini L;Perrotte P;Jeldres C.Nephrectomy improves the survival of patients with locally advanced renal cell carcinoma[J],2008(11).
2Flanigan RC;Salmon SE;Blumenstein BA.Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer[J],2001(23).
3Mickisch GH;Garin A;van Poppel H.Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma:a randomised trial[J],2001(9286).
4Motzer RJ;Bacik J;Mariani T.Treatment outcome and survival associated with metastatic renal cell carcinoma of non-clear-cell histology[J],2002(09).
5Patard JJ;Leray E;Rioux-Leclercq N.Prognostic value of histologic subtypes in renal cell carcinoma:a multicenter experience[J],2005(12).
6Ratain MJ;Eisen T;Stadler WM.Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma[J],2006(16).
7Nanus DM;Garino A;Milowsky MI.Active chemotherapy for sarcomatoid and rapidly progressing renal cell carcinoma,2004(07).
8Oevermann K;Buer L;Hoffmann R.Capecitabine in the treatment of metastatic renal cell carcinoma[J],2000(05).
1Wilhelm SM, Carter C, Tang L, et al. BAY43-9006 exhibits broad spectrum oral anti tumor activity and targets the Raf/ MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res, 2004, 64: 7099-7109.
2Jonasch E, Haluska FG. Interferon in oncotogical practice: review of interferon biology, clinical applications and toxicities. Oncologist, 2001, 6: 34-55.
3Romerio F, Zella D. MEK and ERK inhibitors enhance the anti-proliferative effect of interferon alpha 2b. Faseb J, 2006, 16:1680 1682.
4Gollob JA, Rathmell WK, Richmond TM,et al. Phase Ⅱ trial of sorafenib plus interferon alfa-2b as first- or second-line therapy in patients with metastatic renal cell cancer. J Clin Oncol, 2007, 25: 3288-3295.
5Ryan CW, Goldman BH, Lara PN Jr, et al. Sorafenib with interferon alfa-2b as first-line treatment of advanced renal carcinoma: a phase n study of the Southwest Oncology Group. J Clin Oncol, 2007, 25:3296 3301.
6Bracarda S, Porta C, Boni C, et al. A randomized prospective phase Ⅱ trial of two schedules of sorafenib daily and interfer-on-α2b (IFN) in metastatic renal cell carcinoma (MRCC) (RAPSODY): GOIRC Study 0681. J Clin Oncol, 2007, 25 (Suppl) :357.
7Escudier B, Eisen T, Stadler WM, et al. Sorafenib in advanced clear cell renal cell carcinoma. N Engl J Med, 2007, 356: 125-134.
8Ryan CW, Bukowski RM, Figlin RA, et al. The Advanced Renal Cell Carcinoma Sorafenib (ARCCS) expanded access trial: Long term outcomes in first-line patients (pts). J Clin Oncol, 2007, 25: 5096.
9Motzer RJ, Mazumdar M, Bacik J, et al. Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J Clin Oncol, 1999, 17: 2530-2540.
10Janzen NK, Kim HL, Figlin RA, et al. Surveillance after radical or partial nephrectomy for localized renal cell carcinoma and management of recurrent disease. Urol Clin North Am, 2003, 30, 843-852.
6Bamias A, Manios E, Karadimou A, et al. The use of 24 h ambulatory blood pressure monitoring (ABPM) during the first cycle of sunitinib improves the diagnostic accuracy and management of hypertension in patients with advanced renal cancer[J-.Eur J Cancer, 2011- 47:1660-1668.
7Bettinger D, Schultheiss M, KnUppel E, et al. Diarrhea predicts a positive response to sorafenib in patients with advanced hepatocellular carcinomaEJ].Hepatology, 2012:56:789-790.
8Maroto JP, Del Muro XG, Mellado B, et al. Phase II trial of sequential subcutaneous interleukin-2 plus interferon alpha followed by sorafenib inrenal cell eareinoma(RCC) [J].Clin Transl 0ncol. 2013:15:698-704.
9Colombo JR,Haber GP,Aron M,et al.Oncological outcomea of laparoscopic radical nephreectomy for renal cancer[J].Clinics(Sao Paulo,Brazil),2007,62(3):251-256.
10Torre L A, Bray F, Siegel R L, et al. Global cancer sta- tistics, 2012[J]. CA Cancer J Clin, 2015,65(2):87- 108.
